Agios pivots away from oncology, auctioning off cancer pipeline for $2B and shifting the spotlight in restructuring
Agios made its name as a cancer drug developer under the legendary founder David Schenkein, who took the company from a famously blank sheet of paper to commercialization before he stepped aside a couple of years ago and handed the reins to Celgene vet Jackie Fouse. But now Fouse, who’s had to contend with some setbacks along the way, has a whole new future in mind.
And it doesn’t have anything to do with cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,300+ biopharma pros reading Endpoints daily — and it's free.